RT Journal Article
T1 Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders
A1 Navarro, Gemma
A1 Morales, Paula
A1 Jagerovic, Nadine
A1 Franco, Rafael
A1 Rodríguez Cueto, Carmen Aurora
A1 Fernández Ruiz, José Javier
AB Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs), namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson's disease, Huntington's chorea, cerebellar ataxia, amyotrohic lateral sclerosis). Differential localization of CB2 receptors in neural cell types and upregulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration. Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.
PB Frontiers Media
SN 1662-453X
YR 2016
FD 2016-09-13
LK https://hdl.handle.net/20.500.14352/93212
UL https://hdl.handle.net/20.500.14352/93212
LA eng
DS Docta Complutense
RD 9 abr 2025